Development for new transduction of gene by using mouse monoclonal antibody or its humanized antibody
Development for new transduction of gene by using mouse monoclonal antibody or its humanized antibody
批准号:
08457363
负责人:
SHIMIZU Keiji
金额:
$4.42万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
1996
资助国家:
日本
项目状态:
已结题
起止时间:
1996 至 1998
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The glioma-associated antigen, which mouse monoclonal antibody ONS-M21 (Br J Cancer, 1999) recognized, was integrin alpha3. The expression of integrin alpha3 in the normal brain has been reported to be very low or even undetectable. It appears that the level of this antigen expressed in glioma is correlated with the grade of malignancy and invasion. It is, therefore, very important to investigate integrin alpha3 in glioma cells in order to expect the prognosis of their patients. On the other hand, in the experimental gene therapy of glioma with retroviral vectors reconstructed brain-specific promoter, myelin basic protein (MBP) promoter (Hum Gene Ther, 1997 ; Gene Ther, 1998), it is demonstrated that mouse glioma models were completely recovered with intraperitoneal administration of ganciclovir (GCV), if herpes simplex thymidine kinase (HTK) could be introduced into about 25 % of glioma cells. To obtain high-titer recombinant retroviruses, we constructed plasmid pDL^#, which carries t … More he extended Psi region and the polyomavirus early region, including the replication origin and the early gene. Then we modified the packaging cell lines, PA317, by stably introducing the polyomavirus early gene, and established PAMP5 1 from PA317 cells (Hum Gene Ther, 1998). In vivo experiments by using these high-titer recombinant retroviruses, 80 % of mouse glioma models were completely recovered (Hum Gene Ther, in submitted). In this way we could get very effective vectors, but we could not get therapeutic effects at all by these vectors, if tumor does not have retrovirus receptors. For the tumors that did not have these receptors, we investigated the delivery of HTK genes into glioma cells in vivo using hemagglutinating virus of Japan (HVJ)-liposomes, which are coated by Sendai virus envelope protein. Highly efficient delivery was observed in disseminated glioma cells of MG mice, and 8O0/c of these mice expressing the HTK gene were cured by administration of GCV (Gene Ther, 1997). And moreover, we will thoroughly investigate more specific gene therapy for glioma by HVJ liposome-binding humanized (Mol Immunol, 1995) or single-chain antibodies (Anticancer Res, 1998). When humans medulloblastoma ONS-76 cells were co-cultured with ONS-M21 antibodies, about 20% antibodies were internalized into these cells for less than 30 minutes (Cancer lett, 1998). A cytotoxic effect against ONS-76 cells was found by the iminunotoxin which was bounded with ricin A chain and ONS-M21 antibodies, but not against antigen-negative human hepatoma HuH-7 and colon cancer SW480 cells. These results suggest that ONS-M2 I antibodies could effectively deliver toxins, chemotherapeutic agents or radionuclei to malignant glioma specifically. Now we, however, try to transduce HTK genes into the glioma cells by installments, because the molecular weight of HTK genes-binding ONS-M21 is too big to introduce HTK gene complex by the lump. Less
期刊论文(52)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Moriuchi S: "Decreased N-myc expression in human medulloblastoma cell lines during differentiation." Antiancer Res. 17(1). 301-306 (1997)
Moriuchi S:“人髓母细胞瘤细胞系在分化过程中 N-myc 表达降低。”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Moriuchi S: "Decreased N-myc expression in human medulloblastoma cell lines during differentiation." Anticancer Res. 17. 301-306 (1997)
Moriuchi S:“人髓母细胞瘤细胞系在分化过程中 N-myc 表达降低。”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Yamada M: "In vitro study on intrathecal use of 5-fluoro-2'-deoxyuridine (FdUrd) for meningeal dissemination of malignant brain tumors." J Neuro-oncol. (in press). (1998)
Yamada M:“鞘内使用 5-氟-2-脱氧尿苷 (FdUrd) 治疗恶性脑肿瘤脑膜播散的体外研究。”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kishima H: "Systemic interleukin-12 displays antitumor activity in the mouse central nervous system." Br J Cancer. (in press). (1998)
Kishima H:“全身性白细胞介素 12 在小鼠中枢神经系统中显示出抗肿瘤活性。”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Mabuchi E: "Gene delivery by HVJ-liposome in the experimental gene therapy of murine glioma." Gene Ther. (in press).
Mabuchi E:“在小鼠神经胶质瘤的实验性基因治疗中通过 HVJ 脂质体进行基因传递。”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 42 条
Effect of abnormalities in asymmetric cell divisions of neural stem cells on brain tumor initiation
-
批准号:23659690
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.33万
-
财政年份:2011
-
负责人:SHIMIZU Keiji
-
依托单位:
New therapeutic strategies for malignant brain tumors by using genetic and molecular biology
-
批准号:16390411
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$9.15万
-
财政年份:2004
-
负责人:SHIMIZU Keiji
-
依托单位:
Basic research of malignant glioma-specific gene therapy by using very high titer retrovirus vectors
-
批准号:12470290
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$9.15万
-
财政年份:2000
-
负责人:SHIMIZU Keiji
-
依托单位:
Moleculo-biological analysis for mechanism of proliferation and differentiation in glioma cells and its clinical application
-
批准号:04454360
-
项目类别:Grant-in-Aid for General Scientific Research (B)
-
资助金额:$3.58万
-
财政年份:1992
-
负责人:SHIMIZU Keiji
-
依托单位:
Tumorigenicity and Analysis of the Cell Growth of Human Medulloblastoma
-
批准号:01570809
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.34万
-
财政年份:1989
-
负责人:SHIMIZU Keiji
-
依托单位:
Immunological conditions of patients with malignant gliomas ---Therapeutic drugs and Selection of BRMs---
-
批准号:62570656
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.15万
-
财政年份:1987
-
负责人:SHIMIZU Keiji
-
依托单位:
Identity and their origins of immune cells in the brain
-
批准号:60570671
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$0.96万
-
财政年份:1985
-
负责人:SHIMIZU Keiji
-
依托单位:
海外基金